Skip to main
  1. Stocks
  2. Tyra Biosciences
  3. Forecast
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is attractive fundamentally because its lead dabogratinib program is showing a convincing exposure-response relationship in FGFR3-altered bladder cancer, with 60mg QD delivering 57% 3-month CR and 64% best overall CR in the broader cohort, while safety has remained clean with no Grade 3 treatment-related AEs or discontinuations. The company’s cash position of $700.5M at 3Q26, together with the stated runway through 2030, reduces financing risk and supports multiple upcoming catalysts, including 2027 readouts in SURF302, SURF303, and BEACH301. Its pipeline also addresses large unmet-need settings such as adjuvant NMIBC, LG-UTUC, and achondroplasia, where higher dosing, favorable tolerability, and potentially broader efficacy could expand the commercial opportunity.

Bears say

Tyra Biosciences is viewed negatively because its lead assets still face material clinical and regulatory risk, with TYRA-300 potentially failing to show differentiated safety or efficacy and the broader pipeline needing to prove it can overcome the toxicity and resistance issues that limited first-generation pan-FGFR inhibitors. The company also appears vulnerable on commercial and revenue execution, while ABSK061’s baseline delta lacks a clean comparison to 52-week randomized ACH benchmarks, and Abbisko’s disclosure does not provide enough data to validate efficacy versus peer programs. Peer results from BridgeBio, Ascendis, and BioMarin underscore the bar Tyra must clear, and lavengratinib’s higher-dose 6-month data by YE26 would need to approach 5.9-6.0cm/year before BEACH301 can be viewed as truly competitive.

Tyra Biosciences (TYRA) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction

Get the latest Tyra Biosciences (TYRA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Tyra Biosciences (TYRA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction

Get the latest Tyra Biosciences (TYRA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Tyra Biosciences (TYRA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TYRA stock data and trends